J&J Says Second Dose of its Vaccine Increases Protection Against COVID-19
Efficacy in the U.S. was 94 percent
A second shot of the Johnson & Johnson vaccine boosts protection against symptomatic and severe COVID-19, the disease caused by the coronavirus, the drug company announced early Tuesday. Those booster shots also generated additional antibodies, molecules churned out by the immune system to help fight off infections.
Under the Food and Drug Administration’s (FDA) emergency use authorization, the Johnson & Johnson vaccine is given as a single dose, unlike the two shots required for full immunization with the Pfizer-BioNTech and Moderna mRNA vaccines.
Results published this summer indicate that the Johnson & Johnson vaccine generates lasting amounts of antibodies able to target the delta variant and other variants of concern. In June and July, when delta was ascendant, the effectiveness of the one-shot vaccine was 78 percent against observed COVID-19, according to a report published Thursday that has not yet gone through peer review.
Please select this link to read the complete article from The Washington Post.